Notícias Clearside Biomedical Inc - CLSD | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Clearside Biomedical Inc (CLSD)
Clearside Biomedical Inc (CLSD) Notícias

Clearside Biomedical Inc (CLSD)

0,93

-0,04

(-4,12%)

Fechado 20 Dezembro 6:00PM

Atrasado por 15 minutos

0,94

0,01

(1,08%)

Após o horário de negociação: 8:17PM

Atrasado por 15 minutos

Discussões em tempo real e ideias de negociação: Negocie com confiança com nossa poderosa plataforma.

Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye

Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States

Form 8-K - Current report

Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

Form 4 - Statement of changes in beneficial ownership of securities

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

Form 8-K - Current report

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Clearside Biomedical

Department of Haute Savo...

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições